{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053917","form_type":"8-K","ticker":"MD","cik":"0000893949","company_name":"Pediatrix Medical Group, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.343774+00:00","generated_at":"2026-06-02T21:29:11.214399+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Pediatrix Medical Q1 GAAP EPS $0.05 vs $0.17 YoY; revenue up slightly to $495M","bullets":["Net revenue $495M vs $491M YoY; same-unit revenue up 2.3%.","Net income $4M down from $14.2M; GAAP EPS $0.05 vs $0.17.","Adjusted EPS $0.20 vs $0.23; Adjusted EBITDA $37M vs $40.1M.","FY 2024 Adjusted EBITDA guidance reaffirmed $200M-$220M.","Cash used in ops $122.6M; total debt $705M at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053917","json":"https://secwatch.observer/filing/0000950170-24-053917.json","markdown":"https://secwatch.observer/filing/0000950170-24-053917.md","text":"https://secwatch.observer/filing/0000950170-24-053917.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/893949/000095017024053917/0000950170-24-053917-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/893949/000095017024053917/md-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T21:29:11.214399+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f53d2f4485e27ccd13353ce3ac2dc3aafd78fc91","claim":"Pediatrix Medical Group, Inc. reported the three months ended March 31, 2024 results: revenue $495.1 million, net income $4.0 million, EPS $0.05 per diluted share. Guidance reaffirmed.","evidence_excerpt":"ended March 31, 2024. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.20. For the 2024 first quarter, Pediatrix reported the following results: • Net revenue of $495 million; • Net income of $4 million; and • Adjusted EBITDA of $37 million. “Our first quarter operating results were in line with our expectations,” said James D. Swift, M.D., Chief","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/893949/000095017024053917/0000950170-24-053917-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$495.1 million"},{"label":"Net income","value":"$4.0 million"},{"label":"EPS","value":"$0.05 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}